GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dechra Pharmaceuticals PLC (LSE:DPH) » Definitions » Gross Margin %

Dechra Pharmaceuticals (LSE:DPH) Gross Margin % : 54.70% (As of Jun. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Dechra Pharmaceuticals Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Dechra Pharmaceuticals's Gross Profit for the six months ended in Jun. 2023 was £210.1 Mil. Dechra Pharmaceuticals's Revenue for the six months ended in Jun. 2023 was £384.1 Mil. Therefore, Dechra Pharmaceuticals's Gross Margin % for the quarter that ended in Jun. 2023 was 54.70%.


The historical rank and industry rank for Dechra Pharmaceuticals's Gross Margin % or its related term are showing as below:

LSE:DPH' s Gross Margin % Range Over the Past 10 Years
Min: 53.35   Med: 56.21   Max: 57.08
Current: 55.98


During the past 13 years, the highest Gross Margin % of Dechra Pharmaceuticals was 57.08%. The lowest was 53.35%. And the median was 56.21%.

LSE:DPH's Gross Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 46.8 vs LSE:DPH: 55.98

Dechra Pharmaceuticals had a gross margin of 54.70% for the quarter that ended in Jun. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Dechra Pharmaceuticals was 0.30% per year.


Dechra Pharmaceuticals Gross Margin % Historical Data

The historical data trend for Dechra Pharmaceuticals's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dechra Pharmaceuticals Gross Margin % Chart

Dechra Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.68 56.61 56.89 56.44 55.98

Dechra Pharmaceuticals Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.85 56.77 56.12 57.29 54.70

Competitive Comparison of Dechra Pharmaceuticals's Gross Margin %

For the Drug Manufacturers - General subindustry, Dechra Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dechra Pharmaceuticals's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dechra Pharmaceuticals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Dechra Pharmaceuticals's Gross Margin % falls into.



Dechra Pharmaceuticals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Dechra Pharmaceuticals's Gross Margin for the fiscal year that ended in Jun. 2023 is calculated as

Gross Margin % (A: Jun. 2023 )=Gross Profit (A: Jun. 2023 ) / Revenue (A: Jun. 2023 )
=426.3 / 761.5
=(Revenue - Cost of Goods Sold) / Revenue
=(761.5 - 335.2) / 761.5
=55.98 %

Dechra Pharmaceuticals's Gross Margin for the quarter that ended in Jun. 2023 is calculated as


Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=210.1 / 384.1
=(Revenue - Cost of Goods Sold) / Revenue
=(384.1 - 174) / 384.1
=54.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Dechra Pharmaceuticals  (LSE:DPH) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Dechra Pharmaceuticals had a gross margin of 54.70% for the quarter that ended in Jun. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Dechra Pharmaceuticals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Dechra Pharmaceuticals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Dechra Pharmaceuticals (LSE:DPH) Business Description

Traded in Other Exchanges
Address
24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, GBR, CW9 7UA
Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

Dechra Pharmaceuticals (LSE:DPH) Headlines

No Headlines